EcoDrugPlus

Beta-2 Adrenergic Receptor-Like

Ensembl ID : ENSNFUG00015013743
Gene Symbol: LOC107372451
3 Cross references
195 Possible Orthologues:

Beta-Secretase 1

Ensembl ID : ENSNFUG00015012642
Gene Symbol: BACE1
1 Cross references
218 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSNFUG00015024172
Gene Symbol: BDKRB2
1 Cross references
161 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSNFUG00015024165
Gene Symbol: BDKRB2
1 Cross references
246 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSNFUG00015024162
Gene Symbol: BDKRB2
1 Cross references
246 Possible Orthologues:

Breakpoint Cluster Region Protein-Like

Ensembl ID : ENSNFUG00015021672
Gene Symbol: LOC107393491
3 Cross references
196 Possible Orthologues:

Breakpoint Cluster Region Protein-Like

Ensembl ID : ENSNFUG00015013587
Gene Symbol: LOC107397213
3 Cross references
205 Possible Orthologues:

Camp-Specific 3',5'-Cyclic Phosphodiesterase 4b-Like

Ensembl ID : ENSNFUG00015006192
Gene Symbol: LOC107384393
3 Cross references
224 Possible Orthologues:

Camp-Specific 3',5'-Cyclic Phosphodiesterase 4c-Like

Ensembl ID : ENSNFUG00015004124
Gene Symbol: LOC107389102
3 Cross references
193 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1c Subunit

Ensembl ID : ENSNFUG00015008516
Gene Symbol: CACNA1C
1 Cross references
213 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1d Subunit, A

Ensembl ID : ENSNFUG00015014157
Gene Symbol: CACNA1DA
1 Cross references
211 Possible Orthologues:

Calcium Channel, Voltage-Dependent, P/q Type, Alpha 1a Subunit, B

Ensembl ID : ENSNFUG00015002454
Gene Symbol: CACNA1AB
1 Cross references
192 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).